Physician profile
Raul J Rodriguez
NPI 1467475913
$31,189.36
in general payments reported to CMS, 2019-2025
34 companies · $2,148 in 2025
The $2,148 reported for 2025 was more than what 90% of Addiction Psychiatry providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,593 · 2020: $8,479 · 2021: $3,036 · 2022: $4,703 · 2023: $5,336 · 2024: $2,893 · 2025: $2,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,074 · Consulting Fee: $3,300 · Education: $3.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,074.04 |
| Consulting Fee | $3,300.00 |
| Education | $3.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Brainsway USA INC | $21,913.51 | 2019-2024 | Brainsway Deep Tms System |
| Abbvie INC. | $1,547.82 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $1,239.09 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $1,033.76 | 2020-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $517.91 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $449.14 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Lundbeck LLC | $418.93 | 2023-2025 | Rexulti |
| Almatica Pharma LLC | $384.64 | 2022-2024 | Loreev Xr, Sertraline Hcl |
| Janssen Pharmaceuticals, INC | $378.87 | 2021-2025 | Invega Sustenna, Spravato |
| Corium, LLC | $353.39 | 2022-2025 | Azstarys |
| Indivior INC. | $346.04 | 2019-2025 | Sublocade |
| Orexo US, INC. | $329.86 | 2019-2024 | Zubsolv |
| Neurocrine Biosciences, INC. | $325.12 | 2019-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $300.33 | 2019-2024 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $284.07 | 2020-2025 | Caplyta |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $233.91 | 2023-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $196.29 | 2023-2025 | Auvelity |
| Braeburn INC. | $189.59 | 2023-2025 | Brixadi |
| E.R. Squibb & Sons, L.L.C. | $173.65 | 2025 | Cobenfy |
| Bausch Health US, LLC | $97.72 | 2019-2025 | Wellbutrin |
| Eisai INC. | $85.54 | 2020-2022 | |
| Allergan, INC. | $68.44 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $60.26 | 2022-2023 | Quviviq |
| Livanova USA, INC. | $46.74 | 2023-2025 | Vns Therapy Symmetry Model 8103 Generator |
| Gilead Sciences, INC. | $38.61 | 2019-2020 | |
| Neuronetics, INC. | $35.94 | 2019 | |
| Neos Therapeutics, Lp | $30.24 | 2024 | Adzenys Xr-Odt |
| Tempus Ai, INC | $26.78 | 2024 | |
| Validus Pharmaceuticals LLC | $18.37 | 2025 | Raldesy |
| Novo Nordisk INC | $17.00 | 2023 | Wegovy |
| Sunovion Pharmaceuticals INC. | $16.35 | 2021 | |
| Merck Sharp & Dohme LLC | $15.99 | 2022 | |
| Hikma Pharmaceuticals USA | $15.46 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raul Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.